LINC00311 is overexpressed in ankylosing spondylitis and predict treatment outcomes and recurrence

BMC Musculoskelet Disord. 2019 Jun 7;20(1):278. doi: 10.1186/s12891-019-2647-4.

Abstract

Background: LncRNA LINC00311 participates in osteoporosis, which shows inverse pathological changes to ankylosing spondylitis (AS), indicating that LINC00311 is also involved in AS.

Methods: All the participants were enrolled in Ganzhou People's Hospital between January 2016 and January 2018 after this study was approved by Ganzhou People's Hospital Ethics Committee. Disease activity determination, follow-up and RT-qPCR were carried out during the research.

Results: In the present study we found that LINC00311 was upregulated in AS patients comparing to healthy controls, and upregulation of LINC00311 distinguished AS patients from healthy controls. LINC00311 expression levels were positively correlated with disease activity. Comparing to pre-treatment levels, LINC00311 expression level decreased significantly after treatment. During 2-year follow-up, patients with high levels of LINC00311 showed a significantly higher rate of rehospitalization.

Conclusions: Therefore, LINC00311 is overexpressed in AS and predict treatment outcomes and recurrence.

Keywords: Ankylosing spondylitis; Re-hospitalization; lncRNA LINC00311.

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Biomarkers / blood
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Healthy Volunteers
  • Humans
  • Low Back Pain / blood*
  • Low Back Pain / diagnosis
  • Low Back Pain / drug therapy
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • RNA, Long Noncoding / blood*
  • Recurrence
  • Severity of Illness Index
  • Spondylitis, Ankylosing / blood
  • Spondylitis, Ankylosing / diagnosis*
  • Spondylitis, Ankylosing / drug therapy
  • Treatment Outcome
  • Up-Regulation
  • Young Adult

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • RNA, Long Noncoding